Bottino J, McCredie K B, Ho D W, Freireich E J, Buckles R, Herbst S, Lawson M
Cancer. 1979 Jun;43(6):2197-201. doi: 10.1002/1097-0142(197906)43:6<2197::aid-cncr2820430606>3.0.co;2-1.
Eighty-six patients with acute leukemia were given 116 continuous intravenous arabinosyl cytosine (Ara-C) infusions (for 24 to 432 hours) with a new portable infusion device. The infusor is powered by interchangeable elastomeric 25 ml balloon reservoirs loaded from standard syringes. The reservoir contents are discharged at nearly constant pressure through an adjustable resistance element, thereby providing flow rates from 0.4 to 2.0 ml/hour. Serum levels of labeled Ara-C delivered by the infusor were found to achieve steady-state therapeutic levels within 24 hours. The average-flow-rate-to-indicator-setting ratio determined for each infusion via scalp vein needles was 0.9 +/- 0.2. Delivery through catheters was more reliable and an average-flow-rate-to-indicator-setting ratio of 0.1 +/- 0.1 was observed. The therapeutic effectiveness of Ara-C in combination with other agents was not compromised by this delivery system. Eleven of 14 patients who received all their induction Ara-C through the infusor achieved complete remission.
86例急性白血病患者使用一种新型便携式输注装置接受了116次连续静脉注射阿糖胞苷（Ara-C）（持续24至432小时）。该输注器由可互换的弹性体25毫升球囊储液器驱动，储液器从标准注射器中装填。储液器中的内容物通过一个可调节的阻力元件以近乎恒定的压力排出，从而提供0.4至2.0毫升/小时的流速。发现由该输注器输送的标记阿糖胞苷的血清水平在24小时内达到稳态治疗水平。通过头皮静脉针进行的每次输注所确定的平均流速与指示器设置比率为0.9±0.2。通过导管输送更可靠，观察到平均流速与指示器设置比率为0.1±0.1。这种输送系统并未损害阿糖胞苷与其他药物联合使用的治疗效果。通过输注器接受所有诱导期阿糖胞苷治疗的14例患者中有11例实现了完全缓解。
